ROS1阳性NSCLC靶向药物盘点~
克唑替尼——毫无争议的第一选择
塞瑞替尼——ORR高达62%
Lorlatinib——脑转移患者疗效明显
Taletrectinib——中国患者的新选择
[1]Wu YL,Yang JC,Kim DW,et al.Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.J Clin Oncol.2018 May 10;36(14):1405-1411.doi:10.1200/JCO.2017.75.5587.Epub 2018 Mar 29.PMID:29596029.
[2]Haruko Daga,Seiji Niho,Jun Sakakibara-Konishi,et al.Phase II study of brigatinib in ROS1 positive non-small cell lung cancer(NSCLC)patients previously treated with crizotinib:Barossa cohort 2.abstract J Clin Oncol 39,2021(suppl 15;abstr 9040).
[3]Drilon A,Siena S,Dziadziuszko R,et al.Entrectinib in ROS1 fusion-positive non-small-cell lung cancer:integrated analysis of three phase 1-2 trials.Lancet Oncol.2020 Feb;21(2):261-270.doi:10.1016/S1470-2045(19)30690-4.Epub 2019 Dec 11.Erratum in:Lancet Oncol.2020 Feb;21(2):e70.Erratum in:Lancet Oncol.2020 Jul;21(7):e341.PMID:31838015;PMCID:PMC7811790.
[4]Lim SM,Kim HR,Lee JS,et al.Open-Label,Multicenter,Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.J Clin Oncol.2017 Aug 10;35(23):2613-2618.doi:10.1200/JCO.2016.71.3701.Epub 2017 May 18.PMID:28520527.
[5]Shaw AT,Solomon BJ,Chiari R,et al.Lorlatinib in advanced ROS1-positive non-small-cell lung cancer:a multicentre,open-label,single-arm,phase 1-2 trial.Lancet Oncol.2019 Dec;20(12):1691-1701.doi:10.1016/S1470-2045(19)30655-2.Epub 2019 Oct 25.PMID:31669155.
[6]Turning Point Therapeutics reports early interim data from registrational phase 2 Trident-1 study of repotrectinib,provides regulatory update.News release.Turning Point Therapeutics,Inc.August 19,2020.Accessed August 19,2020.
[7]Caicun Zhou,Huijie Fan,Yongsheng Wang,et al.Taletrectinib(AB-106;DS-6051b)in metastatic non-small cell lung cancer(NSCLC)patients with ROS1 fusion:Preliminary results of TRUST..abstract J Clin Oncol 39,2021(suppl 15;abstr 9066).
[8]Drilon A,Rekhtman N,Arcila M,et al.Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer:an open-label,single-centre,phase 2,single-arm trial.Lancet Oncol.2016 Dec;17(12):1653-1660.doi:10.1016/S1470-2045(16)30562-9.Epub 2016 Nov 4.PMID:27825636;PMCID:PMC5143197.
本文首发:医学界肿瘤频道
本文
本文作者:会飞的大胖纸
联系客服